Show simple item record

dc.contributor.authorKichloo, Asim
dc.contributor.authorJamal, Shakeel
dc.contributor.authorAlbosta, Michael
dc.contributor.authorKhan, Muhammad Zia
dc.contributor.authorAljadah, Michael
dc.contributor.authorEdigin, Ehizogie
dc.contributor.authorAmir, Rawan
dc.contributor.authorWani, Farah
dc.contributor.authorUl-Haq, Ehtesham
dc.contributor.authorKanjwal, Khalil
dc.date.accessioned2021-06-23T16:57:54Z
dc.date.available2021-06-23T16:57:54Z
dc.date.issued2021-06-19
dc.identifier.urihttp://hdl.handle.net/10713/16075
dc.description.abstractPurpose: Using National Inpatient Database (NIS), comparison of clinical outcomes for patients primarily admitted for atrial fibrillation/flutter with and without a secondary diagnosis of amyloidosis was done. Inpatient mortality was the primary outcome and hospital length of stay (LOS), mean total hospital charges, odds of undergoing cardiac ablation, pharmacologic cardioversion, having a secondary discharge diagnosis of heart block, cardiogenic shock and cardiac arrest were secondary outcomes. Methods: NIS database of 2016, 2017 was used for only adult hospitalizations with atrial fibrillation/flutter as principal diagnosis with and without amyloidosis as secondary diagnosis using ICD-10 codes. Multivariate logistic with linear regression analysis was used to adjust for confounders. Results: 932,054 hospitalizations were for adult patients with a principal discharge diagnosis of atrial fibrillation/flutter. 830 (0.09%) of these hospitalizations had amyloidosis. Atrial fibrillation/flutter hospitalizations with co-existing amyloidosis have higher inpatient mortality (4.22% vs 0.88%, AOR: 3.92, 95% CI 1.81-8.51, p = 0.001) and likelihood of having a secondary discharge diagnosis of cardiac arrest (2.40% vs 0.51%, AOR: 4.80, 95% CI 1.89-12.20, p = 0.001) compared to those without amyloidosis. Conclusions: Hospitalizations of atrial fibrillation/flutter with co-existing amyloidosis have higher inpatient mortality and odds of having a secondary discharge diagnosis of cardiac arrest compared to those without amyloidosis. However, LOS, total hospital charges, likelihood of undergoing cardiac ablation, pharmacologic cardioversion, having a secondary discharge diagnosis of heart block and cardiogenic shock were similar between both groups.en_US
dc.description.urihttps://doi.org/10.1016/j.ipej.2021.06.005en_US
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofIndian Pacing and Electrophysiology Journalen_US
dc.rightsCopyright © 2021 Indian Heart Rhythm Society. Production and hosting by Elsevier B.V. All rights reserved.en_US
dc.subjectamyloidosisen_US
dc.subjectatrial fibrillationen_US
dc.subjectconduction disordersen_US
dc.titleIncreased inpatient mortality in patients hospitalized for atrial fibrillation and atrial flutter with concomitant amyloidosis: Insight from National Inpatient Sample (NIS) 2016-2017en_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.ipej.2021.06.005
dc.identifier.pmid34153477
dc.source.countryNetherlands


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record